Pfizer has discontinued development of its experimental daily obesity pill, danuglipron, after a trial participant experienced a potential drug-induced liver injury. The drug was in early-stage testing, aiming to determine the optimal dosage before moving to late-stage trials and regulatory submission. This decision impacts both the once-daily and combination therapy versions of danuglipron.
The pharmaceutical market for obesity treatments is lucrative, with injectable options like Eli Lilly's Mounjaro achieving significant sales ($5 billion in 2024). Pfizer's decision, while ending development of this specific drug, does not signal a withdrawal from the obesity treatment market entirely; the company plans to continue developing other potential treatments.
Despite the market success of injectable treatments, significant access barriers remain. Shortages and high costs (hundreds of dollars monthly) hinder patient access, even with recent price cuts from major manufacturers like Lilly and Novo Nordisk. This highlights the ongoing need for accessible and effective obesity treatment options.
AP —
Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.
The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment.
The once-daily version of the pill was in early-stage testing, with researchers trying to figure out the best dose for patients, a spokeswoman said. The company intended to move the drug into late-stage testing, which is generally the last phase of development before a company submits the potential treatment to government regulators for approval.
A company official said in a statement that Pfizer still plans to develop other potential obesity treatments in earlier stages of testing.
Obesity treatments have become one of the more promising and lucrative sectors of drug development for pharmaceutical companies. Eli Lilly and Co.’s Zepbound, for instance, brought in nearly $5 billion in sales in 2024, its first full year on the market.
But leading treatments like Zepbound and Novo Nordisk’s Wegovy are injectable. Drugmakers are eager to develop an easier-to-take pill version for patients who don’t want to deal with needles and daily injections.
Lilly researchers expect to see data this year from studies of a couple potential oral treatments it has developed.
While the drugs have become top-sellers, many patients have had a hard time getting them either due to recently concluded shortages or patchy insurance coverage. Both Lilly and Novo have recently announced price cuts, but the treatments can still cost hundreds of dollars a month, putting them out of reach for some people without coverage.
Pfizer said in late 2023 that it would abandon a twice-daily version of danuglipron that had adavnced to mid-stage testing after more than half the patients in a clinical trial stopped taking it.
A company spokeswoman said the decision announced Monday meant Pfizer would also stop testing danuglipron in combination with other drugs to treat obesity.
Shares of New York-based Pfizer Inc. advanced 12 cents to $22.03 in morning trading Monday.
If you often open multiple tabs and struggle to keep track of them, Tabs Reminder is the solution you need. Tabs Reminder lets you set reminders for tabs so you can close them and get notified about them later. Never lose track of important tabs again with Tabs Reminder!
Try our Chrome extension today!
Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more